GlassScriptPhysician profile
Lani R Landry
NPI 1679347207
$1,331.59
in general payments reported to CMS, 2019-2025
25 companies · $620 in 2025
The $620 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $711 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $359.53 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $146.93 | 2024 | Contrave, Onzetra Xsail |
| Revance Therapeutics, INC. | $103.62 | 2025 | Daxxify |
| Astrazeneca Pharmaceuticals LP | $71.06 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Noven Therapeutics, LLC | $64.72 | 2024-2025 | Xelstrym |
| Jazz Pharmaceuticals INC. | $61.26 | 2024-2025 | |
| Neos Therapeutics, LP | $59.86 | 2024 | Adzenys Xr-Odt |
| Shield Therapeutics INC | $56.61 | 2024-2025 | |
| Ardelyx, INC. | $41.62 | 2024-2025 | Ibsrela |
| Tolmar, INC. | $36.85 | 2024-2025 | Jatenzo |
| Exact Sciences Corporation | $31.78 | 2024-2025 | Cologuard Collection Kit |
| Acella Pharmaceuticals, LLC | $31.36 | 2024 | NP Thyroid 60 |
| Tris Pharma INC | $30.06 | 2024 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $25.14 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $24.13 | 2024-2025 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.83 | 2025 | |
| Lundbeck LLC | $22.58 | 2025 | Rexulti |
| Astellas Pharma US INC | $21.46 | 2024 | Veozah |
| Ironshore Pharmaceuticals INC. | $20.17 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.29 | 2025 | |
| Amgen INC. | $18.58 | 2025 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.11 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $15.13 | 2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $15.12 | 2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.79 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lani Landry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.